SCHEMBL9917423

SCHEMBL9917423

Cc1ccc(Cn2cc3cc(C)c(Br)cc3n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
DUSP3 P51452 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPC1 O15118 6/20 0.40
HDAC6 Q9UBN7 1/20 0.39
KMT2A Q03164 5/20 0.37
HDAC1 Q13547 1/20 0.36
MEN1 O00255 3/20 0.35
PTGS2 P35354 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
PARK7 Q99497 1/20 0.34
CACNA1G O43497 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9917429 0.94 RAB9A (0.41) RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1
SCHEMBL9917441 0.90 HDAC6 (0.48) RAB9ANPC1HDAC6KMT2AMEN1
SCHEMBL16418008 0.88 RAB9A (0.44) RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1
SCHEMBL9917442 0.84 HDAC6 (0.48) RAB9ANPC1HDAC6KMT2AMEN1
SCHEMBL16772292 0.81 SMN1; SMN2 (0.45) RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1
SCHEMBL9917424 0.81 RAB9A (0.42) RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1
SCHEMBL9917431 0.75 LMNA (0.49) RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1
SCHEMBL9917422 0.74 HDAC6 (0.54) RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1
SCHEMBL9917440 0.72 HDAC6 (0.47) RAB9ASMN1; SMN2NPC1HDAC6KMT2A
SCHEMBL22912929 0.72 MAPT (0.40) RAB9ASMN1; SMN2NPC1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9149463-B2 Methods and compositions of treating a Flaviviridae family viral infection THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) 2015-10-06 US disclosed
US-20150152064-A1 METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2015-06-04 US disclosed
US-8940730-B2 Methods and compositions of treating a Flaviviridae family viral infection THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-01-27 US disclosed
US-8940730-B2 Methods and compositions of treating a Flaviviridae family viral infection THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-01-27 US disclosed
US-20120148534-A1 METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120148534-A1 METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION EIF2AK2, NSUN3, NSUN2 RAB9A 2617/4885SMN1; SMN2 2247/4885DUSP3 358/4885
US-20150152064-A1 METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION EIF2AK2, NSUN3, NSUN2 RAB9A 2617/4885SMN1; SMN2 2247/4885DUSP3 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.